SEATTLE, WASHINGTON -- (Marketwired) -- 03/30/15

Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation") (TSX VENTURE: VPT) is pleased to announce that is has appointed PYP Enterprises LLC (PYP) to be the exclusive distributor to the US military hospitals including the VA hospitals.

The Veterans Health Administration (VHA) is the largest integrated health care system in the United States and consists of 150 medical centers, nearly 1,400 community-based outpatient clinics, community living centers, Vet Centers and Domiciliaries. With a medical care budget of more than $55 billion, VHA employs more than 288,000 staff with 53,000 independent licensed health care practitioners who provide comprehensive care to more than 8.3 million veterans each year. In addition, VHA is the nation's largest provider of graduate medical education and a major contributor to medical research.

"We are well-known to the US Department of Defense and VHA and have already begun to inform them about the unique benefits of the VMS heart analysis system," stated Pio Pype, President and CEO of PYP Enterprises LLC.

"Veterans deserve the best healthcare possible and it is appropriate we work with PYP to bring the VMS heart analysis system to VA hospitals and other military healthcare centres", said Dr. George Adams, President and CEO of Ventripoint.

The VMS™ is approved for clinical use for selected cardiac indications in Canada, Europe and the United States.

About PYP Enterprises LLC

PYP Enterprises LLC is a preferred provider of services to the Department of Defense and is designated as a service-disabled, veteran-owned, small business (SDVOSB) by the US Department of Defense. The US Department of Defense is required to purchase products worth 6% of its budget from SDVOSBs and the VA is required to spend 3% of its annual budget on products from SDVOSBs.

About Ventripoint Diagnostics Ltd.

Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate tool for measuring right ventricle heart function. The Corporation has a suite of applications for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure and normal hearts - a multi-billion dollar market potential.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

FORWARD-LOOKING STATEMENTS: The statements made in this news release that are not historical facts may contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at www.sedar.com. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Contacts:
Ventripoint Diagnostics Ltd.
Dr. George Adams
CEO
(206) 910-9125
gadams@ventripoint.com